Tempo4h
Online Loans Disbursed by Licensed Fintech Companies Hit Rp978tn
Cumulative online loan disbursements by licensed P2P lending companies have reportedly reached nearly Rp1,000 trillion.
Tempo5h
Top 5 Richest Ministers in Prabowo's Red and White Cabinet
Let's take a look at the top five richest ministers based on information from the KPK's State Officials' Wealth Report (LHKPN ...
Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year
Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...
Managed Healthcare Executive13h
FDA Adds Boxed Warning to MS Drug Copaxone
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...
Managed Healthcare Executive13h
BLA Accepted for Melanoma Combination Therapy, RP1 and Nivolumab
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
Zacks.com on MSN17h
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...
The Pharma Letter20h
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
Strong Buy Rating for Replimune Group Due to Promising RP1 + Opdivo Results and Favorable FDA Review
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...
Replimune price target raised to $21 from $17 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares.